Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Aplindore

Small molecule · developed by Ligand Pharmaceuticals

Phase 2 Most advanced trial (none active)
LGND Developer
1 Registered trials

What is Aplindore?

Aplindore is an oral tablet studied in early stage Parkinson's disease, dosed at 0.05 to 5 mg twice daily.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Neurology
Developer
Ligand Pharmaceuticals (LGND)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
Q5O76TA0ML

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00623324 Phase 2 Early Stage Parkinson's Disease Completed LGND

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Early Stage Parkinson's Disease

More from Ligand Pharmaceuticals

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LGND page.

Follow LGND, the company behind Aplindore

See LGND's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LGND catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.